Mark J. Gergen
Overview
Mark J. Gergen received an average of $3M in total compensation, including $518K in salary, at Poseida Therapeutics from 2020 to 2023. Mark Gergen also received an average of $2M at Halozyme Therapeutics between 2016 and 2017 and an average of $1M at Mirati Therapeutics from 2013 to 2016.
- 2023
- 2022
- 2021
- 2020
- 2017
- 2016
- 2015
- 2014
- 2013
Poseida TherapeuticsChief Executive Officer, President and Chairman
Poseida TherapeuticsChief Executive Officer, President and Chairman
Poseida TherapeuticsChief Executive Officer and President and former Chief Business Officer
Poseida TherapeuticsChief Executive Officer and President and former Chief Business Officer
Halozyme TherapeuticsFormer Senior Vice President and Chief Operating Officer
Halozyme TherapeuticsSenior Vice President and Chief Operating Officer
Mirati TherapeuticsFormer Executive Vice President and Chief Operations Officer
Mirati TherapeuticsFormer Executive Vice President and Chief Operations Officer
Mirati TherapeuticsExecutive Vice President and Chief Operations Officer
Mirati TherapeuticsExecutive Vice President and Chief Operations Officer
Source: SEC filings on April 25, 2024, April 26, 2023, April 27, 2022, March 22, 2018, March 24, 2017, April 20, 2017, April 19, 2016, and April 23, 2015.
Related executives
We found 30 more executives who work or worked at Poseida Therapeutics, Halozyme Therapeutics, andMirati Therapeutics.
Kristin Yarema
Poseida Therapeutics
President, Cell Therapy
Brent Warner
Poseida Therapeutics
President, Gene Therapy
Eric Ostertag
Poseida Therapeutics
Chief Executive Officer
Harry Leonhardt
Poseida Therapeutics
General Counsel
Helen Torley
Halozyme Therapeutics
Chief Executive Officer
Masaru Matsuda
Halozyme Therapeutics
General Counsel
Michael LaBarre
Halozyme Therapeutics
Senior Vice President, Chief Technical Officer
Elaine Sun
Halozyme Therapeutics